Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.
The jury in its verdict on Tuesday agreed with Insulet that EOFlow stole the Acton, Massachusetts-based company’s secrets in order to create a competitor to Insulet’s Omnipod, a wearable insulin pump for diabetes patients.
Spokespeople for EOFlow did not immediately respond to a request for comment on the verdict. Insulet president Jim Hollingshead said the company was “extremely